Curigliano G, Hu X, Dent R, Yonemori K, et al. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol 2026 Mar 2:S0923-7534(26)00071-2. doi: 10.1016/j.annonc.2026.
PMID: 41780642